Avandia provides new combination option for patients with inadequately controlled type 2 diabetes

September 17, 2000

Jerusalem, Israel, 18 September 2000: AvandiaTM (rosiglitazone), SmithKline Beecham's oral anti-diabetic agent recently approved in Europe, provides a new combination option for patients with inadequately controlled type 2 diabetes.

Previously, obese, type 2 diabetes patients unable to maintain good glycaemic control with metformin faced limited treatment options, a problem shared by patients failing on sulphonylureas where metformin is contraindicated, i.e. those with renal impairment. Yet management of these patients is critical in slowing disease progression and delaying the use of insulin.

Now, the launch of AvandiaTM provides these patients with new combination regimens. Data presented at the annual conference of the European Association for the Study of Diabetes (EASD), by Dr Tracey Jones of SmithKline Beecham, show that adding AvandiaTM (up to 8 mg/day) to metformin improves blood glucose levels in obese patients. The studies, which involved 550 type 2 diabetes patients, showed fasting plasma glucose was reduced by 3.6 mmol/l compared to baseline.1 Glycosylated haemoglobin (HbA1c) levels were also reduced by nearly 1%; importantly this reduction was maintained for at least 18 months.2 The combination of metformin and AvandiaTM was also found to improve insulin sensitivity and reduce fasting insulinaemia.

In addition, studies involving over 800 patients with type 2 diabetes show that combining AvandiaTM (4 mg/day) with a sulphonylurea in those with mild-to-moderate renal impairment decreases fasting plasma glucose by 2.1 mmol/l, compared with baseline.3 Presenting these data, Arvind Agrawal of SmithKline Beecham concluded: "AvandiaTM provides effective glycaemic control and is well tolerated in patients with renal impairment who are inadequately controlled by sulphonylurea monotherapy, offering hope to this important group of patients."

The ability of AvandiaTM to complement metformin and sulphonylurea therapy may lie with its novel mode of action. AvandiaTM addresses insulin resistance and declining ?-cell function -- two key underlying factors in type 2 diabetes.4,5 Obesity is virtually always associated with insulin resistance,6 making AvandiaTM a rational choice in combination with metformin for obese individuals with poor glycaemic control -- the patient group associated with the highest treatment costs.7 As such, AvandiaTM represents a significant advance in the choice of oral anti-diabetic agents and combination therapy regimens.
SmithKline Beecham -- one of the world's leading healthcare companies -- discovers, develops, manufactures, and markets pharmaceuticals and vaccines, over the counter medicines, health-related consumer products. For company information, visit SmithKline Beecham on the World Wide Web at www.sb.com.

Note to Editors:

AvandiaTM (rosiglitazone) is the first PPAR (peroxisome proliferator-activated receptor) gamma agonist (thiazolidinedione; glitazone) to receive a product licence in the EU via the centralised procedure. AvandiaTM is now available in more than 50 countries worldwide. SmithKline Beecham has committed to a programme of clinical investigations worth more than £100 million in Europe alone -- one of the biggest diabetes programmes recorded.

AvandiaTM is a trademark of SmithKline Beecham plc.


1. Jones T, Jones NP & Sautter M. Addition of rosiglitazone to metformin is effective in obese, insulin-resistant patients with type 2 diabetes. Abstract EASD 2000.

2. SmithKline Beecham. Data on file. 2000. ADVF0330b

3. Agrawal A, Jones NP & Sautter M. Rosiglitazone added to a sulphonylurea in patients with type 2 diabetes and mild-to-moderate renal impairment. Abstract EASD 2000.

4. Porter LE, Freed MI, Jones NP, et al. Rosiglitazone reduces proinsulin/insulin ratio and improves ?-cell function in type 2 diabetes. Abstract EASD 2000.

5. Matthews DR, Bakst A, Weston WM, Hemyari P. Rosiglitazone decreases insulin resistance and improves ?-cell function in patients with type 2 diabetes. Abstract EASD 1999.

6. Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 1997; 46:3--10.

7. Mera R, Wisner CL, Kirsch J, et al. The Cost Of Diabetes in Europe - Type 2 Study: poorly controlled obese diabetic patients are more costly than non-obese patients. Abstract EASD 2000.

Press contact: Jane Nichols and Chloe Murray at MediTech Media on:
(on-site mobile) +972 (0)50 372295 or +44 [0]20 7398 0500

Graeme Holland at SmithKline Beecham on: +44 [0]1279 644369

MediTech Media Ltd.

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.